Sarepta Therapeutics

(NASDAQ) SRPT

Current Price$16.81

Market Cap$1.79B

Since IPO (1997)-57%

5 Year-79%

1 Year-57%

1 Month-19%

Sarepta Therapeutics Financials at a Glance

Market Cap

$1.79B

Revenue (TTM)

$2.18B

Net Income (TTM)

$65.06M

EPS (TTM)

$-0.96

P/E Ratio

-17.59

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$16.81

Volume

1,959,125.242

Open

$16.90

Price

$16.81

Volume

1,959,125.242

Open

$16.90

Previous Close

$16.80

Daily Range

$16.76 - $17.21

52-Week Range

$10.41 - $43.92

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$16.81

Volume

1,959,125.242

Open

$16.90

Previous Close

$16.80

Daily Range

$16.76 - $17.21

52-Week Range

$10.41 - $43.92

SRPT News

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?

David Jagielski, CPAJul 4, 2024

Physician giving a high five to a young patient

1 Soaring Growth Stock to Buy and Hold for 10 Years

Prosper Junior BakinyJul 3, 2024

1 Top Growth Stock to Buy and Hold for 10 Years

Prosper Junior BakinyMay 1, 2024

investor ponders phone and laptop stock charts

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

Alex CarchidiMar 13, 2024

Page 1

SRPT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sarepta Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

835

CEO

Douglas S. Ingram

Website

www.sarepta.com

Headquarters

Cambridge, MA 02142, US

SRPT Financials

Key Financial Metrics (TTM)

Gross Margin

62%

Operating Margin

-2%

Net Income Margin

Return on Equity

-5%

Return on Capital

-2%

Return on Assets

Earnings Yield

-5.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.79B

Shares Outstanding

105.58M

Volume

1.96M

Avg. Volume

3.03M

Financials (TTM)

Gross Profit

$1.32B

Operating Income

$657.77M

EBITDA

$647.97M

Operating Cash Flow

$205.48M

Capital Expenditure

$101.97M

Free Cash Flow

$307.45M

Cash & ST Invst.

$939.65M

Total Debt

$1.04B

Sarepta Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$730.80M

-1.9%

Gross Profit

$611.44M

+0.7%

Gross Margin

83.67%

N/A

Market Cap

$1.79B

N/A

Market Cap/Employee

$1.31M

N/A

Employees

1,372

N/A

Net Income

$330.96M

+174.0%

EBITDA

$375.48M

+201.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$383.48M

+53.3%

Accounts Receivable

$547.91M

-24.4%

Inventory

$1.00B

+6.3%

Long Term Debt

$1.04B

-22.9%

Short Term Debt

$0.00

N/A

Return on Assets

2.05%

N/A

Return on Invested Capital

-1.53%

N/A

Free Cash Flow

$204.76M

+67.5%

Operating Cash Flow

$202.68M

+65.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AGIOAgios Pharmaceuticals, Inc.

AGIOAgios Pharmaceuticals, Inc.$28.14-2.26%

MLYSMineralys Therapeutics, Inc.

MLYSMineralys Therapeutics, Inc.$29.85-1.26%

ETNB89bio, Inc.

ETNB89bio, Inc.$14.84+0.00%

ADPTAdaptive Biotechnologies Corporation

ADPTAdaptive Biotechnologies Corporation$13.88+0.07%

RXRXRecursion Pharmaceuticals, Inc.

RXRXRecursion Pharmaceuticals, Inc.$3.01-3.22%

RCUSArcus Biosciences, Inc.

RCUSArcus Biosciences, Inc.$23.43-1.84%

BEAMBeam Therapeutics Inc.

BEAMBeam Therapeutics Inc.$28.64+3.51%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

FFord Motor Company

FFord Motor Company$14.93+0.09%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.85+0.02%

NIONio

NIONio$5.20-0.07%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.26+0.04%

INFQInfleqtion

INFQInfleqtion $16.35+0.11%

TET1 Energy Inc.

TET1 Energy Inc.$8.08-0.07%

FUTUFutu

FUTUFutu$89.76-0.28%

Questions About SRPT

What is the current price of Sarepta Therapeutics?

Sarepta Therapeutics is trading at $16.80 per share.

What is the 52-week range for Sarepta Therapeutics?

Over the past 52 weeks, Sarepta Therapeutics has traded between $10.42 and $43.92.

How much debt does Sarepta Therapeutics have?

As of the most recent reporting period, Sarepta Therapeutics reported total debt of $1.04B.

How much cash does Sarepta Therapeutics have on hand?

Sarepta Therapeutics reported $464.45M in cash and cash equivalents in its most recent financial results.

What is Sarepta Therapeutics’s dividend yield?

Sarepta Therapeutics does not currently have a dividend yield.

Sarepta Therapeutics

Sarepta Therapeutics Financials at a Glance

SRPT News

2 Beaten-Down Stocks That Could Sink Even More in 2026

Is This Stock a Buy After Soaring by 20% in 1 Day?

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

After a Big Win, Is Sarepta Therapeutics Stock a Buy?

Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?

1 Soaring Growth Stock to Buy and Hold for 10 Years

1 Top Growth Stock to Buy and Hold for 10 Years

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

SRPT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Sarepta Therapeutics

SRPT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Sarepta Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About SRPT

What is the current price of Sarepta Therapeutics?

What is the 52-week range for Sarepta Therapeutics?

How much debt does Sarepta Therapeutics have?

How much cash does Sarepta Therapeutics have on hand?

What is Sarepta Therapeutics’s dividend yield?

Premium Investing Services